Effect of fluticasone propionate on acute and chronic inflammation.
Johnson
M
M
Glaxo Research and Development, Uxbridge, Middlesex, UK.
D000208:Acute Disease; D000281:Administration, Intranasal; D000730:Androstadienes / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D004353:Drug Evaluation, Preclinical; D004802:Eosinophilia / Q000139:chemically induced / Q000517:prevention & control; D000068298:Fluticasone; D006168:Guinea Pigs; D006636:Histamine Release / Q000187:drug effects; D007249:Inflammation / Q000188:drug therapy*; D008407:Mast Cells / Q000187:drug effects / Q000378:metabolism; D011654:Pulmonary Edema / Q000139:chemically induced / Q000517:prevention & control; D051381:Rats; D014051:Toluene 2,4-Diisocyanate / Q000633:toxicity
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D014051:Toluene 2,4-Diisocyanate; D000068298:Fluticasone